

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : National Phase Entry PCT/EP2003/007786
Applicant : Axel ULLRICH et al
Filed : Herewith
TC/A.U. :
Examiner :

Docket No. : 2923-679

Customer No. : 6449

Confirmation No. :

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report. We understand that the references have been forwarded by the International Bureau, and are available to the Examiner, but if the Examiner needs copies of any of the references, the Examiner is requested to advise counsel accordingly.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

By



Robert B. Murray
Attorney for Applicant
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

RBM/cb

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	National Phase Entry of PCT/EP2003/007786 10/521,410
				Filing Date	Herewith
				First Named Inventor	Axel ULLRICH et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet		of	3	Attorney Docket Number	2923-679

FOREIGN PATENT DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>		
				Application Number	National Phase Entry of PCT/EP2003/007786 101521410	
				Filing Date	Herewith	
				First Named Inventor	Axel ULLRICH et al	
				Group Art Unit		
				Examiner Name		
				Confirmation No.		
Sheet			of	3	Attorney Docket Number	2923-679

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	4.	Domagala et al., "Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction", AMERICAN JOURNAL OF PATHOLOGY, vol. 136, no. 1, 1990, pgs. 219-228.			T ²
	5.	Bachmeier et al., "Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity", ANTICANCER RESEARCH, vol. 21, no. 6A, November 2001, pgs. 3821-3828.			
	6.	Attar et al., "Axl receptor tyrosine kinase expression in human breast cancer", BREAST CANCER RESEARCH AND TREATMENT, (Oct. 1997), vol. 46, no. 1, pp. 91			
	7.	Dodge et al., "MCF-10A-NeoST: A new cell system for studying cell-ECM and cell-cell interactions in breast cancer", CLINICAL CANCER RESEARCH, 7/11, (3640-3648) November 2001.			
	8.	Fridell et al., "GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 12, 20 March 1998, pgs. 7123-7126.			
	9.	Wu et al., "Clinical significance of AXL kinase family in gastric cancer", ANTICANCER RESEARCH, (2002 Mar-Apr) 22 (2B) 1071-8.			
	10.	Meric et al., "Expression profile of tyrosine kinases in breast cancer", CLINICAL CANCER RESEARCH, 8/2 (361-367), February 2002.			
	11.	Berclaz et al., "Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast", ANNALS OF ONCOLOGY, (2001 Jun) 12 (6) 819-24.			
	12.	Krupitza et al., "Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells", BRITISH JOURNAL OF CANCER, vol. 73, no. 4, 1 February 1996, pgs. 433-438.			
	13.	Ito et al., "Expression of receptor-type tyrosine kinase, Ax1, and its ligand, gas6, in pediatric thyroid carcinomas around chernobyl", THYROID, vol. 12, no. 11, 1 November 2002, pgs. 971-975.			
	14.	Sasaki et al., "Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains", JOURNAL OF			

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

				Complete if Known	
Application Number				National Phase Entry of PCT/EP2003/007786 107524410	
Filing Date				Herewith	
First Named Inventor				Axel ULLRICH et al	
Group Art Unit					
Examiner Name					
Confirmation No.					
Sheet			of	3	Attorney Docket Number
					2923-679

	15.	Pedrocchi et al., "Expression of CA2+-Binding Proteins of the S100 Family in malignant human breast-cancer cell lines and biopsy samples", INTERNATIONAL JOURNAL OF CANCER, vol. 57, no. 5, 1 June 1994, pgs. 684-690.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.